Innoforce Raises $157 Million for Cell Therapy, Gene Therapy and RNA CDMO

Hangzhou Innoforce closed a $59 million tranche that, when added to an earlier $96 million funding in March, brings its Series A round to $157 million. Innoforce is a biopharmaceutical manufacturing & development company. The company will use the proceeds to advance its GMP biomanufacturing capabilities, including increasing cell & gene therapy capacity and growing its RNA manufacturing platform. The funding will also support INF's biopharma R&D facilities, which will create tailored partnerships with entrepreneurial scientists and companies for drug development and other services. More details.... Share this with colleagues: // //